Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

, in Las Vegas, Nevada, brought together a number of key clinicians to share updates and advancements in everything from obesity and diabetes to 

. Trials like CAHtalyst Adult and discussions on topics like GLP-1s in 

 took center stage over the 3-day meeting.

With all of the new data and key perspectives being shared throughout the conference, the editorial team at 

 has collected 5 of the most impactful headlines to come out of AACE 2026. Catch up on any major data you may have missed during the conference below:


Reemphasizing Nutrition and Diet in Managing Chronic Endocrine Disease, With Jeffrey Mechanick, MD


Jeffrey Mechanick, MD, medical director of the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Fuster Heart Hospital, discusses the importance of employing nutritional goals in managing obesity and preventing additional endocrine diseases. Mechanick highlights the interplay between the metabolic system and the exposome, noting that nutrition is far more than simply diet and exercise – and every aspect has an impact on endocrine health.


Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD


2-year data from the CAHtalyst Adult study have shown substantial and sustained reductions in glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) when treated with crinecerfont. In addition to these positive results, Richard Auchus, MD, PhD, professor of pharmacology and internal medicine at the University of Michigan, discusses the substantial retention observed throughout the open-label extension.


Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD


Although the risks of iodine deficiency are well-documented, excess iodine also poses substantial risk to the thyroid – and can be caused through unexpected sources, including common micronutrient supplements and iodized salt. To address this, Shashank Joshi, MD, a consultant endocrinologist at Lilavati Hospital and Joshi Clinic, highlights a narrow iodine window that clinicians should target, given the thyroid’s intolerance of extremes in either direction.


Beyond Insulin: Evaluating GLP-1 RAs as Adjunctive Therapy in Type 1 Diabetes, With Viral Shah, MD


Although T1D treatment is largely reliant on insulin therapy, a significant proportion of patients fail to achieve time in range >70%, driven in part by rising rates of obesity. To this end, Viral Shah, MD, a professor of medicine in the division of endocrinology & metabolism and director of Diabetes Clinical Research at the IU Center for Diabetes and Metabolic Diseases at Indiana University, discusses the potential of implementing GLP-1 medications in T1D. Their well-documented efficacy in reducing excess adiposity, coupled with their potentially beneficial effects for cardiovascular health, make them an attractive potential adjunct to existing insulin therapy.


Diabetes Dialogue: Nutrition, Medication, and Treatment in Obesity With Elizabeth Bauer, MD


In a special on-site episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, meet with Elizabeth Bauer, MD, to discuss her “Year in Review” presentation at AACE. AACE’s updated obesity algorithm, emerging obesity pharmacotherapies, and the management of disease and medication side effects take center stage as Bauer covers the full scope of obesity in both the clinical and patient setting.

Articles

AACE 2026 emphasized integrated endocrine care spanning nutrition, obesity therapeutics, thyroid micronutrient management, and adrenal and diabetes innovations. Nutrition was framed as a targeted metabolic intervention influenced by the exposome, extending beyond diet and exercise. In classic CAH, 2-year CAHtalyst Adult data supported sustained glucocorticoid dose reductions with crinecerfont alongside strong open-label extension retention. Thyroid discussions stressed a narrow therapeutic window for iodine, with both deficiency and excess—often supplement-driven—posing risk. GLP-1 receptor agonists were positioned as potential adjuncts in T1D amid obesity and suboptimal time-in-range.

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

AACE 2026 Recap: 5 Key Presentations to Know

Syed-Mohammed Jafri, MD, is a Gastroenterologist and Transplant Hepatologist at Henry Ford Hospital.

Reducing TPN Burden & Improving Quality of Life in Short Bowel Syndrome

Short bowel syndrome (SBS) remains a life-altering condition, often requiring lifelong reliance on parenteral support to maintain nutrition and hydration. While these therapies are lifesaving, new data presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, highlight a growing recognition among clinicians: the burden of total parenteral nutrition (TPN) extends far beyond clinical stabilization, with significant implications for safety, complications, and quality of life.

Patients with SBS dependent on parenteral support face substantial clinical and lifestyle challenges due to reduced intestinal function. TPN remains the cornerstone of management, but it is associated with a range of complications, including infections, thrombosis, and liver injury.

“We have been continuing to work with patients with short bowel syndrome now for over 15 years, and following these patients over time and really seeing the tough life that they lead,” Syed-Mohammed Jafri, MD, a gastroenterologist and transplant hepatologist at Henry Ford Hospital, told 

The data presented at DDW stemmed from a noninterventional, cross-sectional online survey conducted among HCPs in the US and Europe with ≥2 years of experience treating SBS patients and actively managing ≥1 patient. The survey assessed perceptions of TPN-related complications, clinical burden, and preferred outcome attributes for potential new therapies.

HCPs reported a high burden associated with TPN in patients with SBS dependent on parenteral support, with central line complications, fatigue, and decreased QoL being primary concerns. Reducing time on TPN was considered more impactful than volume reduction.

According to Jafri, the traditional focus on stabilization represents only the first phase of care, pointing to the need for a more comprehensive, long-term management strategy . While TPN can prevent malnutrition and stabilize electrolytes, it also introduces new risks that must be actively managed over time.

The study findings reinforce this perspective, showing that healthcare professionals prioritize minimizing complications and keeping patients out of the hospital. However, there is increasing awareness that treatment goals must extend beyond safety alone.

A central theme of the research is the importance of reducing the burden of TPN, particularly in terms of time. Nearly half of surveyed clinicians identified reducing the number of days per week on TPN as the most valuable outcome, followed by reducing hours per day. By comparison, fewer respondents prioritized reducing infusion volume.

This aligns closely with patient experiences. Many individuals require TPN infusions for up to 12 hours daily, limiting their ability to work, socialize, or leave home. As Jafri noted, patients often seek “a break” from therapy to regain a sense of normalcy in their daily lives .

Beyond quality of life, reducing time on TPN is also clinically beneficial. Fewer infusion hours and days may reduce exposure to central venous catheters, thereby lowering the risk of infections and thrombosis, 2 of the most serious complications identified in the study.

Implications for Clinical Practice and Future Research

These findings signal a shift in how clinicians approach SBS management. While maintaining stability and preventing hospitalizations remain critical, there is growing emphasis on balancing these goals with quality of life considerations. Actively pursuing strategies to wean patients from TPN when feasible is becoming an increasingly important aspect of care.

Looking ahead, there remains a need for innovative therapies that reduce dependence on parenteral support while maintaining nutritional adequacy. Advances in intestinal rehabilitation, improved delivery methods, and novel pharmacologic agents may all contribute to this goal.

Equally important is increasing awareness of SBS within the gastroenterology community. Early recognition and referral to specialized centers can help ensure patients receive comprehensive care tailored to both clinical and lifestyle needs.

Jafri SM, Harrison J, Kumpf V, et al. BURDEN OF TOTAL PARENTERAL NUTRITION FOR PATIENTS WITH SHORT BOWEL SYNDROME DEPENDENT ON PARENTERAL SUPPORT: HEALTHCARE PROFESSIONAL PERSPECTIVES ON RISKS, LIMITATIONS, AND TREATMENT PRIORITIES. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

Videos

New research underscores the risks and daily burden of TPN in SBS, with focus shifting toward reducing dependence and complications.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Time Off TPN Emerging as Key Goal in Short Bowel Syndrome Care, With Syed-Mohammed Jafri, MD

Noreen Galaria, MD, is a board-certified and fellowship-trained dermatologist based in the Washington, D.C. area with over 20 years of experience. She is the founder of Inner Glow Vitamins and practices at Galaria Plastic Surgery & Dermatology.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Skin of Color Savvy: Misinformation, Holistic Dermatology, and Skin of Color, With Noreen Galaria, MD

, Noreen Galaria, MD, a board-certified dermatologist with more than 2 decades of experience, shared insights from her clinical practice and research interests, with a focus on holistic dermatologic care and considerations for patients with skin of color.

Galria runs a private practice and is also the founder of Inner Glow Vitamins, a line of dermatologist-developed skin supplements. Galaria described how her career evolved toward integrating conventional dermatology with naturopathic and internal approaches to skin health, particularly through the use of nutraceuticals and antioxidant-based strategies.

A key theme of the discussion centered on the importance of representation in dermatology. Galaria reflected on how practicing in different geographic regions shaped her awareness of disparities in training and patient care, particularly the limited exposure some clinicians have to diverse skin types. She emphasized how patients with skin of color often seek out physicians who they feel understand their unique concerns, which has informed both her clinical focus and research collaborations, including work addressing hair loss in women who wear head coverings. She highlighted the value of organizations like SOCS in fostering collaboration and advancing research that fills gaps in the literature.

Galaria also addressed ongoing challenges in dermatology, particularly the rise of misinformation driven by social media. While acknowledging that patients today are often more informed, she noted that information quality varies widely, requiring clinicians to guide patients toward evidence-based care tailored to individual skin types and conditions. This individualized approach was echoed in her discussion of treatment strategies, especially for conditions such as melasma and hyperpigmentation, where prevention and management require a more comprehensive understanding of factors like visible light exposure and internal oxidative stress.

The conversation explored the growing interest in internal photoprotection, with Galaria outlining how oral antioxidants, such as polypodium leucotomos and other compounds, can complement traditional sunscreens by addressing cellular damage pathways. She stressed that these approaches are adjunctive rather than replacements for sunscreen and highlighted their potential role in protecting against pigmentation, photoaging, and skin cancer. More broadly, she advocated for a layered, mechanism-based approach to skin health that combines topical and internal therapies.

Additional topics included physician wellness and interdisciplinary collaboration. Galaria emphasized the importance of sustainable self-care practices, such as habit stacking and prioritizing sleep, in addressing burnout. She also highlighted the role of dermatologists in recognizing systemic disease and working with specialists across disciplines to provide comprehensive care. Overall, the discussion underscored a shift toward more holistic, patient-centered dermatology that integrates science, lifestyle, and representation to improve outcomes.

To learn more about SOCS’s programs and initiatives, visit 

Editor’s note: This episode was summarized with the help of AI tools.

Podcasts

In this new Skin of Color Savvy podcast, Noreen Galeria, MD, discusses topics such as patient, misinformation, her career, and research on natural remedies.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Despite a relatively quiet month from the 

, the American College of Cardiology (ACC) Scientific Sessions 2026 more than made up for the lack of regulatory news with a continued series of key trial updates. From 

obstructive hypertrophic cardiomyopathy (oHCM)

, all aspects of cardiology saw significant forward movement during this conference. Additionally, updates to the ABCs of Cardiology and other guidelines in April continued the paradigm shift towards prevention that cardiology has embraced in recent months.

With so many trials reaching their endpoints, the editorial team at 

 has collected 7 of the most impactful headlines from the last 30 days below:


SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS


Presented by Joseph Rossano, MD, MS, co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, new data from the SCOUT-HCM trial have proven mavacamten’s efficacy in reducing left ventricular outflow in adolescent patients with oHCM compared with placebo. Additionally, of the 65 enrolled patients, adverse events occurred in only 18 in the mavacamten arm and 17 in the placebo arm, with only 2 serious adverse events in each group.

CORALreef AddOn: Enlicitide Outperforms Standard Hypercholesterolemia Drugs, With Ann Marie Navar, MD, PhD


The CORALreef AddOn trial has demonstrated enlicitide’s superior reduction of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. The trial compared enlicitide to bempedoic acid, ezetimibe, and a combination thereof – among patients with 

atherosclerotic cardiovascular disease (ASCVD)

, enlicitide saw a substantially higher LDL-C reduction than all 3 comparators. Ann Marie Navar, MD, PhD, discusses the results and their implication for an expected New Drug Application.


Self-Administered Etripamil for PSVT Has Minimal Blood Pressure, Heart Rate Effects, With Narendra Singh, MD


Etripamil nasal spray, recently approved for paroxysmal supraventricular tachycardia (PSVT), has minimal effects on blood pressure, despite a long history of calcium channel blockers leading to hypotension. Parts 1-3 of the NODE-301 trial, assessing heart rate and blood pressure changes in patients treated with a test dose of etripamil, revealed significantly lower blood pressure changes than other CCBs. Narendra Singh, MD, assistant professor at Mercer University Atlanta Campus, director of clinical research at NSC Cardiology, and co-author of NODE-301, spoke on the reassurance that this trial provides for clinicians prescribing etripamil.


Reviewing the Updated ABCs of Cardiovascular Disease Prevention, With Aaron Troy, MD, MPH


The ABCs of Cardiovascular Disease Prevention has recently undergone a major update, highlighting the PREVENT equations and Life’s Essential 8. Additionally, the document now includes 

, largely considered disease-focused areas rather than preventable conditions. Aaron Troy, MD, MPH, clinical research fellow at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center, discusses the value of a more prevention-focused mindset in cardiovascular disease.

CADENCE: Sotatercept Reduces PVR in CpcPH-HFpEF, With Mardi Gomberg-Maitland, MD, MSc


Based on data presented at ACC 2026 by Mardi Gomberg-Maitland, MD, MSc, director of the pulmonary 

 program, chief clinical research officer at the Office of Clinical Research SMHS, and professor of medicine at George Washington University, sotatercept has successfully reduced pulmonary vascular resistance (PVR) in combined post- and pre-capillary pulmonary hypertension (CpcPH) heart failure with preserved ejection fraction (HFpEF). The ongoing CADENCE trial has already shown substantially greater PVR reductions compared to placebo at week 24.


Tonlamarsen Lowers Angiotensinogen, Mixed Results for Blood Pressure, With Luke Laffin, MD


An update from the Kardinal study, provided by Luke Laffin, MD, co-director of the Center for Blood Pressure Disorders and associate professor of medicine at the Cleveland Clinic, has shown that monthly tonlamarsen successfully lowered plasma angiotensinogen in patients with uncontrolled hypertension compared to a single dose. However, it led to no additional blood pressure reduction, indicating the need for further placebo-controlled trials to determine its efficacy in single doses or a multi-dose regimen.

Obicetrapib is Safe and Well-Tolerated in HeFH and ASCVD, With Stephen Nicholls, MD


A pooled safety analysis of the BROADWAY and BROOKLYN phase 3 trials has revealed the safety and tolerability of obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH) and ASCVD. Presented at ACC 2026 by Stephen Nicholls, MD, director of the Monash Victorian Heart Institute at Monash Health, these data indicated less new-onset diabetes, fewer adverse events, and less incidence of hypertension in patients treated with obicetrapib.

April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiomyopathy

Atherosclerotic Cardiovascular Disease

7 Cardiology Headlines You Missed in April 2026

Gil Melmed, MD, is affiliated with Cedars-Sinai Inflammatory Bowel Disease Center.

Which Biologic Lasts Longest for Crohn's Disease? Real-World Switch Rate Data Explained

With a growing roster of advanced therapies available for Crohn's disease (CD), treatment sequencing has become one of the most consequential decisions a gastroenterologist makes. While clinical trial data inform efficacy and safety, they do not capture what happens over the years a patient spends on a given drug in the real world.

A new claims-based analysis presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, offers a different lens, taking a closer look at real-world switch rates. Gil Melmed, MD, a gastroenterologist at Cedars-Sinai, presented data from the US-payer claims database analysis examining real-world switching rates over 24 months among patients with CD initiating risankizumab, adalimumab, infliximab, ustekinumab, or vedolizumab.

“Switch rates are important when we think about therapies for Crohn's disease. It really gives us a sense of what is the anticipated persistence of a drug,” Melmed told 

. “When we offer chronic therapy to a patient with a chronic condition, there's only so much that we can tell from clinical trials, because clinical trials don't tell the whole story.”

The analysis drew on the Merative Marketscan database, identifying 5434 patients ≥ 18 years of age with ≥ 1 inpatient or 2 outpatient claims for CD who initiated a new biologic between January 2022 and July 2025. All patients had a minimum of 6 months of follow-up.

Nonswitching rates, defined as no claim for another advanced therapy, were assessed using Kaplan-Meier analysis over 24 months across the full population and the biologic-naïve subgroup. A Cox proportional hazards model adjusted for baseline differences including age, comorbidity burden, prior surgery, and prior biologic exposure.

At 24 months, risankizumab demonstrated the lowest estimated switch rate of any biologic assessed (14.0% across all patients, 13.4% in the biologic-naïve subgroup). Ustekinumab followed at 21.1% and 19.3%, respectively, with vedolizumab, infliximab, and adalimumab trailing further behind, the latter reaching a switch rate of 36.0% in the overall population.

Of note, the advantage of risankizumab was most pronounced in biologic-naïve patients, consistent with the broader principle that first-line advanced therapy offers the best opportunity for durable response. However, the advantage still persisted even among patients with prior biologic exposure.

“For risankizumab, that switch rate of the persistence of the drug requiring to go on to a different therapy is lowest in risankizumab, meaning that switch rate is lower than it is with other drugs,” Melmed explained. “This effect is more pronounced in patients who are naive to other therapies, as opposed to patients who have previously been on other therapies. And we see that with risankizumab being the lowest switch rate, even in patients who have also been on prior advanced therapies.”

Melmed emphasized that real-world persistence data capture the aggregate effect of efficacy, tolerability, and patient experience over time, something clinical trials cannot. A patient who stops a drug for any reason shows up in switch rate data, making it a composite reflection of how a therapy performs outside of protocol-driven conditions.

The findings are also consistent with switch rate data for risankizumab in other immune-mediated conditions, including psoriasis and psoriatic arthritis, suggesting a durable treatment profile that may extend across indications.

Melmed noted that the claims data did not capture the reasons behind individual switching decisions, an acknowledged limitation that future analyses should aim to address.

Editor's note: Melmed reports relevant disclosures with AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, Janssen, Medtronic, Merck, Prometheus Labs, Pfizer, Takeda, and others.

Melmed G, Ungaro RC, Griffith J, et al. Real-World Switching Rates Among Patients With Crohn's Disease Treated With Biologics in the United States. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

Teeple A, Sah J, Mallampati R, et al. Persistence, Dosing, and Other Treatment Patterns Among Crohn's Disease Patients Initiating Biologics in United States. 

. 2021;3(4):otab076. Published 2021 Nov 5. doi:10.1093/crocol/otab076

Gil Melmed, MD, breaks down real-world data showing risankizumab has the lowest switch rates in Crohn’s over 24 months, highlighting strong persistence vs other biologics.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease

Basile Njei, MD, PhD, MPH, is an assistant professor at Yale School of Medicine.

Njei explains the evolving treatment landscape for MASLD and how it impacts the cost-effectiveness of noninvasive tests for screening.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Optimizing MASLD Screening in the Era of Liver-Directed Therapy, With Basile Njei, MD, PhD, MPH

Stay updated with the latest healthcare breakthroughs, including notable FDA approvals and filings, in this week’s essential news roundup.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 04/26

Jignesh Shah, MD, is a gastroenterologist at Gastroenterology Consultants, PA.

Shah describes the science and real-world use of gluten sensors, with insights on how these tools may support patients with celiac disease without replacing standard care.

The Emerging Role of Gluten Detection Sensors in Celiac Disease Care, With Jignesh Shah, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

7 Dermatology Headlines You Missed in April 2026

Elizabeth Kiracofe, MD, speaks in this segment of her recent The Medical Sisterhood podcast about her career and other community initiatives.

Getting Involved in the Community as a Dermatologist, With Elizabeth Kiracofe, MD

Rachael Sood, NP, is a diabetes nurse practitioner and Owner and CEO of The Diabetes Collective.

Sood shares her thoughts on the recent announcement by the FDA, limiting pharmacies’ ability to compound semaglutide, tirzepatide, and liraglutide from bulk substances.

FDA News

Type 2 Diabetes

FDA Proposes Exclusion of Multiple GLP-1 RAs from Bulks List, With Raechel Sood, NP

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

APOL1 research is driving precision nephrology, but prediction gaps and equity challenges still limit clinical impact.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

APOL1-Mediated Kidney Disease: From Genetic Discovery to the Edge of Precision Medicine

Physician and CEO, Chicago Allergy Center, and board director at American Lung Association

The first single-inhaler ICS/LABA/LAMA combination for asthma adds a mechanistically distinct bronchodilator to a well-established inhaled backbone.

BGF Triple Therapy FDA Approval Expands Asthma Options for Underserved Patients, With Juanita Mora, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA expands lumateperone for relapse prevention in schizophrenia, White House boosts psychedelics research, and AI reshapes psychiatry care debates in April 2026.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

5 Psychiatry Headlines You Missed in April 2026

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

April 2026 saw new data from pivotal clinical trials and a new approval in asthma.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Latest News

AACE 2026 Recap: 5 Key Presentations to Know

Time Off TPN Emerging as Key Goal in Short Bowel Syndrome Care, With Syed-Mohammed Jafri, MD

Skin of Color Savvy: Misinformation, Holistic Dermatology, and Skin of Color, With Noreen Galaria, MD

7 Cardiology Headlines You Missed in April 2026

Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease